- Home
- CD vs RIGL Comparison
CD vs RIGL Comparison
Compare CD & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CD | RIGL |
|---|---|---|
| Founded | 2011 | 1996 |
| Country | United States | United States |
| Employees | 13 | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 470.9M | 564.7M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | CD | RIGL |
|---|---|---|
| Price | $6.29 | $26.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $45.67 |
| AVG Volume (30 Days) | 65.3K | ★ 336.0K |
| Earning Date | 08-31-2023 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1867.68 |
| EPS | N/A | ★ 0.44 |
| Revenue | N/A | ★ $294,282,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.75 |
| P/E Ratio | ★ N/A | $59.34 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $3.09 | $17.67 |
| 52 Week High | $14.10 | $52.24 |
Technical Indicators
Market Signals| Indicator | CD | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 67.98 | 31.86 |
| Support Level | $6.03 | $24.84 |
| Resistance Level | $8.04 | $31.26 |
| Average True Range (ATR) | 0.55 | 1.42 |
| MACD | 0.10 | -0.55 |
| Stochastic Oscillator | 83.25 | 5.13 |
Price Performance
Historical ComparisonAbout CD Chaince Digital Holdings Inc. Ordinary Shares
Chaince Digital Holdings Inc is digital fintech company providing access to the growing AI-powered infrastructure, blockchain, and digital assets. Its three core business lines include: blockchain and digital asset solutions, AI and HPC infrastructure, developing liquid cooling solutions for AI data centers and comprehensive financial services through Chaince Securities,LLC a FINRA-registered broker-dealer, and RIA.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.